获得性免疫缺陷综合征并发巨细胞病毒性视网膜炎的药物治疗现状和进展  

Present status and advances in pharmacotherapy for cytomegalovirus retinitis associated with acquired immunodeficiency syndrome

作　　者：王伟伟[1] 叶俊杰[1] 

机构地区：[1]中国医学科学院北京协和医学院北京协和医院眼科, 100730

出　　处：《中华眼科杂志》2010年第12期1148-1152,共5页Chinese Journal of Ophthalmology

摘　　要：巨细胞病毒性视网膜炎是获得性免疫缺陷综合征晚期最常见、最严重的眼部机会性感染,是导致患者视力丧失的最主要原因.继更昔洛韦、膦甲酸在临床广泛应用后,缬更昔洛韦、西多福韦及福米韦生也已经获得美国药品与食品管理局批准,先后应用于眼科临床,取得了一定的治疗效果.目前,马立巴韦、MSL-109单克隆抗体、Cyclopropavir及BAY 38-4766 正在进行Ⅰ期、Ⅱ期或Ⅲ期临床试验,可望给临床治疗带来新的希望.Cytomegalovirus retinitis has been the most common opportunistic infection and leading cause of visual loss in AIDS patients. There are five drugs approved by the Food and Drug Administration in the USA for the treatment of cytomegalovirus retinitis： ganeiclovir, foscarnet/phosphonoformic acid,valganciclovir, eidofovir and formivirsen. Progress has been made in the treatment of cytomegalovirus retinitis. Nowadays, maribavir, monoclonal antibody MSL-109, cyclopropavir and BAY 38-4766 are entering clinical trials. This review summarizes present status and advances in pharmacotherapy for cytomegalovirus retinitis in AIDS.

关 键 词：巨细胞病毒视网膜炎 获得性免疫缺陷综合征 药物疗法 

分 类 号：R686[医药卫生—骨科学]